Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05108051
Other study ID # ZSP1273-20-05
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 19, 2020
Est. completion date March 17, 2021

Study information

Verified date October 2021
Source Guangdong Raynovent Biotech Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the drug-drug interaction between ZSP1273 and oseltamivir, the pharmacokinetic characteristics and safety of ZSP1273 and oseltamivir in healthy subjects, so as to provide a basis for the design of administration regimen in subsequent clinical trials.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date March 17, 2021
Est. primary completion date March 17, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Males and female subjects between 18-45 years (Both inclusive); - Body weight is no less than 50kg in males and no less than 45kg in females.Body mass index (BMI) 18~26 kg/m2 (Both inclusive); BMI is determined by the following equation: BMI = weight/height2 (kg/m2); - Subjects (including partners) are willing to voluntarily use effective contraception from screening to 3 months after the last study drug administration. Exclusion Criteria: - Known history of allergic constitution (multiple drugs especially with ZSP1273 or oseltamivir and its preparation of the main ingredient allergy, food allergy); - Subjects who donated blood or bleeding profusely(> 450 mL)in the 3 months preceding study screening; - History or presence of any disease or condition known to increase the risk of bleeding, eg.hemorrhoids, acute gastritis or gastric and duodenal ulcer, etc; - Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal within 14 days prior to screening; - Concomitant therapy with any drugs with known hepatic enzyme-inducing or inhibiting agents that may change the activity of drug metabolic enzymes ,is intended to be taken in combination 28 days prior to screening or during the study period; - Participated in another clinical research study or received any investigational products within 3 months prior to dosing; - Presence of clinically significant abnormalities in ECG , QTcB>450ms in males,or QTcB>470ms in females; - Any of the following diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular diseases) that are clinically significant in clinical laboratory examination or other clinical findings within 6 months prior to screening; - Breast-feeding women or those with positive pregnancy test results; - Subjects who should not be included in the study in the opinion of the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ZSP1273
ZSP1273 tablets 600mg administered orally once daily
Oseltamivir
Oseltamivir 75mg administered orally twice daily

Locations

Country Name City State
China Guangdong Provincial Hospital of Chinese Medicine Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Guangdong Raynovent Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma pharmacokinetics Tmax pre-dose and up to 72hours post-dose
Primary Plasma pharmacokinetics t1/2 pre-dose and up to 72hours post-dose
Primary Plasma pharmacokinetics Cmax pre-dose and up to 72hours post-dose
Primary Plasma pharmacokinetics AUC0-8 pre-dose and up to 72hours post-dose
Primary Plasma pharmacokinetics CL/F pre-dose and up to 72hours post-dose
Primary Number of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) TEAEs will be summarized displaying the number of TEAEs along with the number and percentage of participants with at least one TEAE according to: Number of AEs, Severity and relation to study drug. up to 37days
See also
  Status Clinical Trial Phase
Completed NCT05692570 - A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers Phase 1
Completed NCT04328766 - Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers Phase 1
Completed NCT03990129 - Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects Phase 1
Completed NCT03985969 - Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin Phase 1
Completed NCT03302845 - A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects Phase 1
Completed NCT02887443 - A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate Phase 1
Completed NCT01361217 - The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity N/A
Completed NCT06066060 - A DDI Study of JMKX000623 and Metformin Hydrochloride Phase 1
Completed NCT03723395 - A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib Phase 1
Recruiting NCT05789173 - Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK Early Phase 1
Completed NCT04598542 - Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers Phase 1
Recruiting NCT05044962 - Kuwa Free! - Live Free! N/A
Completed NCT04487145 - Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy Phase 4
Active, not recruiting NCT04669678 - Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa Phase 4
Completed NCT01991327 - Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males Phase 1
Completed NCT04218513 - Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection Phase 1
Completed NCT05492318 - Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity Phase 1
Completed NCT01309854 - Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects Phase 1
Recruiting NCT05339672 - Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
Completed NCT05306379 - Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin Phase 1